Stability of Blood Biomarkers of Traumatic Brain Injury.

Blood biomarker tests were recently approved for clinical diagnosis of traumatic brain injury (TBI), yet there are still fundamental questions that need attention. One such question is the stability of putative biomarkers in blood over the course of several days after injury if the sample is unable to be processed into serum or plasma and stored at low temperatures. Blood may not be able to be stored at ultra-low temperatures in austere combat or sports environments. In this prospective study of 20 adult patients with positive head computed tomography imaging findings, the stability of three biomarkers (glial fibrillary acidic protein [GFAP], ubiquitin C-terminal hydrolase-L1 [UCH-L1], and S100 calcium binding protein B [S100B]) in whole blood and in serum stored at 4-5°C was evaluated over the course of 72 h after blood collection. The amount of time whole blood and serum were refrigerated had no significant effect on GFAP concentration in plasma obtained from whole blood and in serum (p = 0.6256 and p = 0.3687, respectively), UCH-L1 concentration in plasma obtained from whole blood and in serum (p = 0.0611 and p = 0.5189, respectively), and S100B concentration in serum (p = 0.4663). Concentration levels of GFAP, UCH-L1, and S100B in blood collected from patients with TBI were found to be stable at 4-5°C for at least 3 days after blood draw. This study suggests that the levels of the three diagnostic markers above are still valid for diagnostic TBI tests if the sample is stored in 4-5°C refrigerated conditions.

[1]  J. Ornato,et al.  Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study , 2018, The Lancet Neurology.

[2]  G. Manley,et al.  The diagnostic values of UCH-L1 in traumatic brain injury: A meta-analysis , 2018, Brain injury.

[3]  G. Iverson,et al.  A Systematic Review of the Usefulness of Glial Fibrillary Acidic Protein for Predicting Acute Intracranial Lesions following Head Trauma , 2017, Frontiers in Neurology.

[4]  E. Steyerberg,et al.  Blood-Based Protein Biomarkers for the Management of Traumatic Brain Injuries in Adults Presenting to Emergency Departments with Mild Brain Injury: A Living Systematic Review and Meta-Analysis , 2017, Journal of neurotrauma.

[5]  D. Menon,et al.  Serial Sampling of Serum Protein Biomarkers for Monitoring Human Traumatic Brain Injury Dynamics: A Systematic Review , 2017, Front. Neurol..

[6]  J. Bazarian,et al.  Utility of Serum Biomarkers in the Diagnosis and Stratification of Mild Traumatic Brain Injury , 2017, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[7]  L. Papa,et al.  Modeling the Kinetics of Serum Glial Fibrillary Acidic Protein, Ubiquitin Carboxyl-Terminal Hydrolase-L1, and S100B Concentrations in Patients with Traumatic Brain Injury. , 2017, Journal of neurotrauma.

[8]  J. Henley,et al.  Ubiquitin C-terminal hydrolase L1 (UCH-L1): structure, distribution and roles in brain function and dysfunction , 2016, The Biochemical journal.

[9]  G. Brophy,et al.  Time Course and Diagnostic Accuracy of Glial and Neuronal Blood Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma Patients With and Without Mild Traumatic Brain Injury. , 2016, JAMA neurology.

[10]  F. Tortella,et al.  Ability of Serum Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and S100B To Differentiate Normal and Abnormal Head Computed Tomography Findings in Patients with Suspected Mild or Moderate Traumatic Brain Injury , 2016, Journal of neurotrauma.

[11]  Yuyuan Li,et al.  Serum ubiquitin C-terminal hydrolase L1 as a biomarker for traumatic brain injury: a systematic review and meta-analysis. , 2015, The American journal of emergency medicine.

[12]  A. Vafaee,et al.  S100B protein as a screening tool for computed tomography findings after mild traumatic brain injury: Systematic review and meta-analysis , 2015, Brain injury.

[13]  Hester F. Lingsma,et al.  Measurement of the glial fibrillary acidic protein and its breakdown products GFAP-BDP biomarker for the detection of traumatic brain injury compared to computed tomography and magnetic resonance imaging. , 2015, Journal of neurotrauma.

[14]  C. Robertson,et al.  GFAP out-performs S100β in detecting traumatic intracranial lesions on computed tomography in trauma patients with mild traumatic brain injury and those with extracranial lesions. , 2014, Journal of neurotrauma.

[15]  Timothy F Cloughesy,et al.  The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings. , 2014, Clinical biochemistry.

[16]  Meilan K. Han,et al.  Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study , 2014, Journal of Translational Medicine.

[17]  Hester F. Lingsma,et al.  Acute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein. , 2014, Journal of neurotrauma.

[18]  Hester F. Lingsma,et al.  GFAP-BDP as an acute diagnostic marker in traumatic brain injury: results from the prospective transforming research and clinical knowledge in traumatic brain injury study. , 2013, Journal of neurotrauma.

[19]  F. Légaré,et al.  Predictive value of S-100β protein for prognosis in patients with moderate and severe traumatic brain injury: systematic review and meta-analysis , 2013, BMJ : British Medical Journal.

[20]  Joseph J Crisco,et al.  Spectrum of acute clinical characteristics of diagnosed concussions in college athletes wearing instrumented helmets: clinical article. , 2012, Journal of neurosurgery.

[21]  J. P. McCoy,et al.  Effect of anticoagulants on multiplexed measurement of cytokine/chemokines in healthy subjects. , 2012, Cytokine.

[22]  P. Middleton Practical use of the Glasgow Coma Scale; a comprehensive narrative review of GCS methodology. , 2012, Australasian emergency nursing journal : AENJ.

[23]  T. Scalea,et al.  Use of Serum Biomarkers to Predict Secondary Insults Following Severe Traumatic Brain Injury , 2012, Shock.

[24]  F. Tortella,et al.  Elevated levels of serum glial fibrillary acidic protein breakdown products in mild and moderate traumatic brain injury are associated with intracranial lesions and neurosurgical intervention. , 2012, Annals of emergency medicine.

[25]  F. Tortella,et al.  Serum levels of ubiquitin C-terminal hydrolase distinguish mild traumatic brain injury from trauma controls and are elevated in mild and moderate traumatic brain injury patients with intracranial lesions and neurosurgical intervention , 2012, The journal of trauma and acute care surgery.

[26]  N. Wilczak,et al.  GFAP and S100B in the acute phase of mild traumatic brain injury , 2012, Neurology.

[27]  A. Gabrielli,et al.  Clinical Utility of Serum Levels of Ubiquitin C-terminal Hydrolase as a Biomarker for Severe Traumatic Brain Injury , 2022 .

[28]  Florian Kronenberg,et al.  Differences between Human Plasma and Serum Metabolite Profiles , 2011, PloS one.

[29]  F. Tortella,et al.  Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study , 2011, Critical care.

[30]  A. Gabrielli,et al.  Biokinetic analysis of ubiquitin C-terminal hydrolase-L1 (UCH-L1) in severe traumatic brain injury patient biofluids. , 2011, Journal of neurotrauma.

[31]  M. Raichle,et al.  Detection of blast-related traumatic brain injury in U.S. military personnel. , 2011, The New England journal of medicine.

[32]  Jackson Streeter,et al.  Blood-based diagnostics of traumatic brain injuries , 2011, Expert review of molecular diagnostics.

[33]  R. Hurley,et al.  Common data elements in radiologic imaging of traumatic brain injury , 2010, Journal of magnetic resonance imaging : JMRI.

[34]  L. Hansson,et al.  Secondary insults following traumatic brain injury enhance complement activation in the human brain and release of the tissue damage marker S100B , 2010, Acta Neurochirurgica.

[35]  Ian N. M. Day,et al.  UCHL1 (PGP 9.5): Neuronal biomarker and ubiquitin system protein , 2010, Progress in Neurobiology.

[36]  D. Streiner,et al.  Regional Variability in the Use of CT for Patients with Suspected Mild Traumatic Brain Injury , 2009, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[37]  E. Leznik,et al.  The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders. , 2007, Drug news & perspectives.

[38]  K. Waterloo,et al.  S100B serum level predicts computed tomography findings after minor head injury. , 2007, The Journal of trauma.

[39]  Sen-Yung Hsieh,et al.  Systematical evaluation of the effects of sample collection procedures on low‐molecular‐weight serum/plasma proteome profiling , 2006, Proteomics.

[40]  W. Mutschler,et al.  SERUM S-100B CONCENTRATION PROVIDES ADDITIONAL INFORMATION FOT THE INDICATION OF COMPUTED TOMOGRAPHY IN PATIENTS AFTER MINOR HEAD INJURY: A PROSPECTIVE MULTICENTER STUDY , 2006, Shock.

[41]  F. Lecky,et al.  Rapid elimination of protein S-100B from serum after minor head trauma. , 2006, Journal of neurotrauma.

[42]  Ewout W Steyerberg,et al.  Prediction of Outcome in Traumatic Brain Injury with Computed Tomographic Characteristics: A Comparison between the Computed Tomographic Classification and Combinations of Computed Tomographic Predictors , 2005, Neurosurgery.

[43]  J. Barrett,et al.  Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. , 2005, Clinical chemistry.

[44]  H. Tammen,et al.  Peptidomic analysis of human blood specimens: Comparison between plasma specimens and serum by differential peptide display , 2005, Proteomics.

[45]  Graham B. I. Scott,et al.  HUPO Plasma Proteome Project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples , 2005, Proteomics.

[46]  Michael Gaetz,et al.  The neurophysiology of brain injury , 2004, Clinical Neurophysiology.

[47]  M. Zimmermann,et al.  Measurements of Serum S-100B Protein: Effects of Storage Time and Temperature on Pre-Analytical Stability , 2003, Clinical chemistry and laboratory medicine.

[48]  A. Brawanski,et al.  Early S-100B serum level correlates to quality of life in patients after severe head injury , 2002, Brain injury.

[49]  C. Alling,et al.  Elimination of S100B and renal function after cardiac surgery. , 2000, Journal of cardiothoracic and vascular anesthesia.

[50]  H. Xiong,et al.  [Pathophysiological alterations in cultured astrocytes exposed to hypoxia/reoxygenation]. , 2000, Sheng li ke xue jin zhan [Progress in physiology].

[51]  Li Chen,et al.  Evidence for an Interaction between Ubiquitin-Conjugating Enzymes and the 26S Proteasome , 2000, Molecular and Cellular Biology.

[52]  C. Price,et al.  The Early Fall in Levels of S-100 β in Traumatic Brain Injury , 2000 .

[53]  T. Ingebrigtsen, B. Romner, S. Marup-Jensen, M. Do The clinical value of serum S-100 protein measurements in minor head injury: a Scandinavian multicentre study , 2000 .

[54]  C. Alling,et al.  The appearance of S-100 protein in serum during and immediately after cardiopulmonary bypass surgery: a possible marker for cerebral injury. , 1997, Journal of cardiothoracic and vascular anesthesia.

[55]  A. Laupacis,et al.  Variation in ED use of computed tomography for patients with minor head injury. , 1997, Annals of emergency medicine.

[56]  D. Harris,et al.  Neurone-specific enolase and Sangtec 100 assays during cardiac surgery: part II - must samples be spun within 30 min? , 1997, Perfusion.

[57]  S. Mirvis,et al.  Trauma Radiology: Part IV. Imaging of Acute Craniocerebral Trauma , 1994, Journal of intensive care medicine.

[58]  J. Vanderhaeghen,et al.  An acidic protein isolated from fibrous astrocytes. , 1971, Brain research.

[59]  R. Richterich,et al.  Der Einfluß der Enteiweißung auf die Resultate von Serum- und Plasma-Analysen , 1967, Klinische Wochenschrift.

[60]  S. Beers,et al.  Serum concentrations of ubiquitin C-terminal hydrolase-L1 and αII-spectrin breakdown product 145 kDa correlate with outcome after pediatric TBI. , 2012, Journal of neurotrauma.

[61]  J. Ziebell,et al.  Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury , 2011, Neurotherapeutics.

[62]  R. Alday,et al.  Sequential computerized tomography changes and related final outcome in severe head injury patients , 2005, Acta Neurochirurgica.

[63]  B. Romner,et al.  The clinical value of serum S-100 protein measurements in minor head injury: a Scandinavian multicentre study. , 2000, Brain injury.

[64]  M. Wiesmann,et al.  Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. , 1999, Clinical chemistry.